Mass General Brigham spun out AIwithCare, a generative AI platform that interprets both structured a...
The AMW Read
The spin-out of a validated clinical tool from a major academic medical center updates the player map for Vertical AI-Healthcare and exemplifies the workflow-driven ROI debate.
NoveltySignificance
Healthcare & Bio Β· Player Map
Mass General Brigham spun out AIwithCare, a generative AI platform that interprets both structured and unstructured clinical data for clinical trial screening. A JAMA study showed enrollment rates nearly double traditional manual screening, addressing a bottleneck that consumes one-third of clinical trial costs. This represents a systemic shift where academic medical centers commercialize validated AI tools, potentially accelerating drug development timelines by 30-50%. The platform's ability to understand clinical context beyond billing codes signals a new era of data-driven clinical operations.
#AI #HealthcareAI #ClinicalTrials #GenerativeAI #DigitalHealth #MedTech #HealthTech #AIinMedicine #ClinicalResearch #DrugDevelopment